Literature DB >> 9751213

Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells.

F Désarnaud1, A N Do Thi, A M Brown, G Lemke, U Suter, E E Baulieu, M Schumacher.   

Abstract

To understand better the mechanisms by which progesterone (PROG) promotes myelination in the PNS, cultured rat Schwann cells were transiently transfected with reporter constructs in which luciferase expression was controlled by the promoter region of either the peripheral myelin protein-22 (PMP22) or the protein zero (P0) genes. PROG stimulated the P0 promoter and promoter 1, but not promoter 2, of PMP22. The effect of PROG was specific, as estradiol and testosterone only weakly activated promoters. Dose-response curves for stimulation of both promoter constructs by PROG were biphasic. RU486, a PROG antagonist, did not abolish the effect of PROG, but stimulated promoter activities by itself. In the human carcinoma cell line T47D expressing high levels of PROG receptor, PROG did not stimulate the P0 and PMP22 promoters, whereas the promoter region of the mouse mammary tumor virus was fully activated. Thus, the activation by PROG of promoter activity of two peripheral myelin protein genes is Schwann-cell specific.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751213     DOI: 10.1046/j.1471-4159.1998.71041765.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  37 in total

Review 1.  Progesterone treatment of spinal cord injury: Effects on receptors, neurotrophins, and myelination.

Authors:  Alejandro F De Nicola; Susana L Gonzalez; Florencia Labombarda; Maria Claudia González Deniselle; Laura Garay; Rachida Guennoun; Michael Schumacher
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 2.  Myelin disorders: Causes and perspectives of Charcot-Marie-Tooth neuropathy.

Authors:  Gerd Meyer zu Hörste; Thomas Prukop; Klaus-Armin Nave; Michael W Sereda
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 3.  Myelin P0: new knowledge and new roles.

Authors:  Joseph Eichberg
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

4.  Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model.

Authors:  Thomas Prukop; Dirk B Epplen; Tobias Nientiedt; Sven P Wichert; Robert Fledrich; Ruth M Stassart; Moritz J Rossner; Julia M Edgar; Hauke B Werner; Klaus-Armin Nave; Michael W Sereda
Journal:  Am J Hum Genet       Date:  2014-03-27       Impact factor: 11.025

Review 5.  Animal models of Charcot-Marie-Tooth disease type 1A.

Authors:  M W Sereda; K-A Nave
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

6.  Progesterone derivatives increase expression of Krox-20 and Sox-10 in rat Schwann cells.

Authors:  Valerio Magnaghi; Marinella Ballabio; Ilaria Roglio; Roberto C Melcangi
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 7.  The PMP22 gene and its related diseases.

Authors:  Jun Li; Brett Parker; Colin Martyn; Chandramohan Natarajan; Jiasong Guo
Journal:  Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.590

8.  Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.

Authors:  Susana L González; Juan José López-Costa; Florencia Labombarda; Maria Claudia González Deniselle; Rachida Guennoun; Michael Schumacher; Alejandro F De Nicola
Journal:  Cell Mol Neurobiol       Date:  2008-06-27       Impact factor: 5.046

9.  SRC-1 is involved in the control of the gene expression of myelin protein Po.

Authors:  Ilaria Teresa Rita Cavarretta; Luciano Martini; Marcella Motta; Carolyn Louise Smith; Roberto Cosimo Melcangi
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

10.  Functional and comparative genomics analyses of pmp22 in medaka fish.

Authors:  Junji Itou; Mikita Suyama; Yukio Imamura; Tomonori Deguchi; Kazuhiro Fujimori; Shunsuke Yuba; Yutaka Kawarabayasi; Takashi Kawasaki
Journal:  BMC Neurosci       Date:  2009-06-17       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.